Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...
Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...
Zacks.com on MSN9h
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
22hon MSN
Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback